Eikon Therapeutics, Inc. (EIKN)

Empfehlung

32,5
Verkaufen
Composite Score (0–100)
Insider (25%)
89.8
5 Insider, 49,6M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
80.4
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)

Score-Verlauf (90 Tage)

Stammdaten

Unternehmen

NameEikon Therapeutics, Inc.
TickerEIKN
CIK0001861123

Branche

SIC-Code2836
BeschreibungBiological Products, (No Diagnostic Substances)

Wertpapier

CUSIP
ISIN
TypCommon Stock
TitelEikon Therapeutics, Inc.

Status

Zuletzt geprüft2026-03-23 10:38:16.839777

Fondsaktivität (letzte 3 Quartale)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-02-06Column Group IV GP, LP10% OwnerOpen Market Purchase1,437,32318.0025,871,814.00+551,3%
2026-02-06Column Group IV GP, LP10% OwnerOpen Market Purchase49,55618.00892,008.00+19,0%
2026-02-06Column Group IV GP, LP10% OwnerOpen Market Purchase630,88118.0011,355,858.00+242,0%
2026-02-04Foresite Capital Management IV, LLC10% OwnerOpen Market Purchase55,55518.00999,990.00+21,3%
2026-02-04FRAZIER KENNETH CDirectorOpen Market Purchase111,11118.001,999,998.00+42,6%
2026-02-04Foresite Capital Management IV, LLC10% OwnerOpen Market Purchase55,55518.00999,990.00+21,3%
2026-02-04Lux Venture Partners V, LLC10% OwnerOpen Market Purchase138,88818.002,499,984.00+53,3%
2026-02-04Lux Venture Partners V, LLC10% OwnerOpen Market Purchase138,88818.002,499,984.00+53,3%
2026-02-04Wolfe JoshDirector, 10% OwnerOpen Market Purchase138,88818.002,499,984.00+53,3%
2026-02-04Foresite Capital Management IV, LLC10% OwnerOpen Market Purchase55,55518.00999,990.00+21,3%
2026-02-04Foresite Capital Management IV, LLC10% OwnerOpen Market Purchase55,55518.00999,990.00+21,3%

Top-Fondshalter (aktuelles Quartal)

Keine Fondsdaten für das aktuelle Quartal vorhanden.